A US drug-agency clampdown is unwarranted without evidence of harm, say Robert C. Green and Nita A. Farahany.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Australians’ views on personal genomic testing: focus group findings from the Genioz study
European Journal of Human Genetics Open Access 30 April 2018
-
Diet and exercise changes following direct-to-consumer personal genomic testing
BMC Medical Genomics Open Access 02 May 2017
-
The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study
BMC Medical Genomics Open Access 15 October 2015
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carver, K. H. Food Drug Law J. 63, 151–215 (2008).
Kalf, R. R. J. et al. Genet. Med. http://dx.doi.org/10.1038/gim.2013.80 (2013).
Swan, M. Genet. Med. 12, 279–288 (2010).
Bloss, C. S. et al. Genet. Med. 12, 556–566 (2010).
Bloss, C. S., Schork, N. J. & Topol, E. J. N. Engl. J. Med. 364, 524–534 (2011).
Green, R. C. et al. N. Engl. J. Med. 361, 245–254 (2009).
Lautenbach, D. M., Christensen, K. D., Sparks, J. A. & Green, R. C. Annu. Rev. Genomics Hum. Genet. 14, 491–513 (2013).
Kaufman, D. J., Bollinger, J. M., Dvoskin, R. L. & Scott, J. A. J. Genet. Couns. 21, 413–422 (2012).
Francke, U. et al. PeerJ 1, e8 (2013).
Topol, E. The Creative Destruction of Medicine (Basic, 2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R.C.G. leads several NIH research projects on genetic disclosure including one completed project, the Impact of Personal Genomics or PGen Study, (R01-HG005092) Scientists from two companies, 23andMe and Pathway Genomics interact with this study but have no control over data, analysis or publications. R.C.G. has, without compensation, contributed self-scripted, non-exclusive educational material to the 23andMe website. R.C.G. has not received personal financial support from any of the above entities; he has received support from the Brin-Wojcicki Foundation for an unrelated sequencing project.
Related links
Related links in Nature Research
Related external links
Listen
Nature’s Kerri Smith looks at the recent FDA crackdown on 23andMe
Rights and permissions
About this article
Cite this article
Green, R., Farahany, N. Regulation: The FDA is overcautious on consumer genomics. Nature 505, 286–287 (2014). https://doi.org/10.1038/505286a
Published:
Issue Date:
DOI: https://doi.org/10.1038/505286a
This article is cited by
-
The epistemic harms of direct-to-consumer genetic tests
Medicine, Health Care and Philosophy (2023)
-
Direct-to-Consumer Genetic Testing and Its Marketing: Emergent Ethical and Public Policy Implications
Journal of Business Ethics (2022)
-
The Interface of Therapeutics and Genomics in Cardiovascular Medicine
Cardiovascular Drugs and Therapy (2021)
-
Australians’ views on personal genomic testing: focus group findings from the Genioz study
European Journal of Human Genetics (2018)
-
Diet and exercise changes following direct-to-consumer personal genomic testing
BMC Medical Genomics (2017)